The United States shows concern regarding the lack of product patent protection for certain pharmaceutical products. As per the Special 301 Report:” U.S. industry also has expressed concern that the regulatory framework in Finland regarding process patents filed before 1995, and pending in 1996, denies adequate protection to many of the top-selling U.S. pharmaceutical products currently on the Finnish market.”
The entire report can be found here.
Source: USTR
